Feedback
Settings

Settings

Goto Application

1. WO2020232165 - BISPECIFIC ANTI-CD3 X CD20 ANTIBODIES AND USES THEREOF

Submit observation
PermaLink
Publication Number WO/2020/232165
Publication Date 19.11.2020
International Application No. PCT/US2020/032738
International Filing Date 13.05.2020
IPC
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C12P 21/08 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21Preparation of peptides or proteins
08Monoclonal antibodies
C12N 5/16 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
12Fused cells, e.g. hybridomas
16Animal cells
C07H 21/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/2809
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2809against the T-cell receptor (TcR)-CD3 complex
C07K 16/2887
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2887against CD20
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/31
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
31multispecific
Applicants
  • QLB BIOTHERAPEUTICS [US]/[US]
Inventors
  • TU, Chao
  • WANG, Rijian
Agents
  • CHEN, Lin
Priority Data
62/847,38314.05.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BISPECIFIC ANTI-CD3 X CD20 ANTIBODIES AND USES THEREOF
(FR) ANTICORPS ANTI-CD3 X ANTI-CD20 BISPÉCIFIQUES ET LEURS UTILISATIONS
front page image
Abstract
(EN)
The disclosure relates to bispecific anti-CD3 x CD20 antibodies comprising (i) a single-chain CD3 binding moiety, (ii) a single-chain CD20 binding moiety, and preferably (iii) an Fc region. Aspects of the disclosure further relate to compositions comprising these bispecific antibodies, vectors comprising one or more polynucleotides encoding these bispecific antibodies, as well as uses of these bispecific antibodies for treating a subject suffering from a B cell-related cancer, in particular, a subject who has developed resistance to anti-CD20, e.g., rituximab, therapy..
(FR)
L'invention concerne des anticorps anti-CD3 X anti-CD20 bispécifiques comprenant (i) une fraction de liaison à CD3 à chaîne unique, (ii) une fraction de liaison à CD20 à chaîne unique, et de préférence (iii) une région Fc. Certains aspects de l'invention concernent en outre des compositions comprenant ces anticorps bispécifiques, des vecteurs comprenant un ou plusieurs polynucléotides codant pour ces anticorps bispécifiques, ainsi que des utilisations de ces anticorps bispécifiques pour traiter un sujet souffrant d'un cancer associé à des cellules B, en particulier, un sujet qui a développé une résistance à anti-CD20, par exemple une thérapie par rituximab.
Latest bibliographic data on file with the International Bureau
# -